Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast

Ratner, Paul H.; Howland, William C.; Arastu, Raiqua; Philpot, E.; Klein, Kristofer C.; Baidoo, Charlotte A.; Faris, Melissa; Rickard, Kathleen

doi:10.1016/s1081-1206(10)61847-9

Cited by 80 publications

(39 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…52 Two additional randomized, double-blind placebo controlled trials have also shown greater improvement in daytime and nighttime nasal symptom scores and individual nasal symptom sores. 53,54 A comparison of montelukast to pseudoephedrine showed comparable control of nasal symptom scores and quality of life scores and increasing peak nasal inspiratory flow rates in the treatment of AR.…”

Section: Monteleukast In Comparison To Other Medicationsmentioning

confidence: 96%

Montelukast: Pharmacology, Safety, Tolerability and Efficacy

Benninger

Waters

2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

Allergic rhinitis and asthma are common disorders effecting large percentages of the population of Western countries. There are multiple treatment options available for allergic rhinitis and asthma and stepwise approaches to therapy have been recommended. Montelukast is a cysteinyl leukotriene receptor antagonist that has been found to be effective both in the treatment of allergic rhinitis and asthma. This paper will describe the pharmacology, safety, efficacy and tolerability of montelukast. It will examine the comparative efficacy of montelukast to other medications for the treatment of allergic rhinitis and asthma, as well as discuss the recent studies of combination therapy.

show abstract

Section: Monteleukast In Comparison To Other Medicationsmentioning

confidence: 96%

Montelukast: Pharmacology, Safety, Tolerability and Efficacy

Benninger

Waters

2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

show abstract

“…A study found that LTRAs reduced the mean daily rhinitis symptom scores by 5% more than placebo [59]. Anti-leukotrienes are less effective than topical nasal corticosteroids [103][104][105][106]. Anti-leukotriene plus antihistamine combinations do not improve efficacy to a clinically relevant extent compared with either drug used alone [107][108][109][110], and their use in rhinitis is thus disputed [111].…”

Section: Anti-leukotrienesmentioning

confidence: 99%

BSACI guidelines for the management of allergic and non‐allergic rhinitis

Scadding

Durham

Mirakian

et al. 2007

Clin Experimental Allergy

349

292

View full text Add to dashboard Cite

SummaryThis guidance for the management of patients with allergic and non-allergic rhinitis has been prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well as on expert opinion and is for use by both adult physicians and paediatricians practicing in allergy. The recommendations are evidence graded. During the development of these guidelines, all BSACI members were included in the consultation process using a web-based system. Their comments and suggestions were carefully considered by the SOCC. Where evidence was lacking, consensus was reached by the experts on the committee. Included in this guideline are clinical classification of rhinitis, aetiology, diagnosis, investigations and management including subcutaneous and sublingual immunotherapy. There are also special sections for children, co-morbid associations and pregnancy. Finally, we have made recommendations for potential areas of future research.

show abstract

“…Indeed, this has been demonstrated in several clinical studies, based both on subjective daily diary data and on several validated instruments assessing sleep quality, sleep-related QOL, and nocturnal rhinitis-related QOL (see Table 2). 23,24,[71][72][73][74][75][76][77][78][79][80] Two small similarly-designed placebo-controlled crossover trials in patients with perennial AR demonstrated significant trends toward improvements in nasal congestion, subjective sleep, and daytime somnolence (as recorded in daily diaries) with INS (flunisolide in one study and budesonide in the other) vs placebo (Figure 2). 23,24 The INS fluticasone has also significantly improved subjective sleep quality vs placebo (p=0.04) in 32 patients with perennial AR and chronic sleep problems.…”

mentioning

confidence: 99%

Allergic rhinitis-induced nasal congestion: its impact on sleep quality

Storms¹

2008

Primary Care Respiratory Journal

View full text Add to dashboard Cite

Allergic rhinitis (AR) is an extremely common health problem affecting 20 to 40 million Americans and between 10-25% of the world's population. Patients with AR suffer from both nasal symptoms (congestion, rhinorrhea, itching, and sneezing) and ocular symptoms (itching, redness, and tearing). The negative impact on sleep quality and quantity, and consequently on various aspects of the patient's life, is an under-recognised and under-treated component of AR morbidity. Nasal congestion, which is one of the most bothersome and prevalent symptoms of AR, is thought to be the leading symptom responsible for rhinitis-related sleep problems.In addition to reducing clinical symptoms, pharmacologic therapies for AR that specifically reduce inflammatory cells and mediators -and therefore nasal congestion and other symptoms -should also improve sleep quality and overall quality of life (QOL). Intranasal corticosteroids (INS) are the current mainstay of therapy for AR. Results of a number of clinical trials demonstrate that INS effectively reduce nasal congestion and ocular symptoms, improve sleep quality, and decrease daytime somnolence. Intranasal corticosteroids have also proved to be effective in reducing symptoms of acute rhinosinusitis and nasal polyposis, both of which also negatively impact on sleep quality. Intranasal corticosteroids are considered safe due to their low systemic bioavailability.

show abstract

Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast

Cited by 80 publications

References 14 publications

Montelukast: Pharmacology, Safety, Tolerability and Efficacy

Montelukast: Pharmacology, Safety, Tolerability and Efficacy

BSACI guidelines for the management of allergic and non‐allergic rhinitis

Allergic rhinitis-induced nasal congestion: its impact on sleep quality

Contact Info

Product

Resources

About